28549178|t|RhoA / Rock Inhibition Improves the Beneficial Effects of Glucocorticoid Treatment in Dystrophic Muscle: Implications for Stem Cell Depletion
28549178|a|Glucocorticoid treatment represents a standard palliative treatment for Duchenne muscular dystrophy (DMD) patients, but various adverse effects have limited this treatment. In an effort to understand the mechanism(s) by which glucocorticoids impart their effects on the dystrophic muscle, and potentially reduce the adverse effects, we have studied the effect of prednisolone treatment in dystrophin / utrophin double knockout (dKO) mice, which exhibit a severe dystrophic phenotype due to rapid muscle stem cell depletion. Our results indicate that muscle stem cell depletion in dKO muscle is related to upregulation of mTOR, and that prednisolone treatment reduces the expression of mTOR and other pro-inflammatory mediators, consequently slowing down muscle stem cell depletion. However, prednisolone treatment was unable to improve the myogenesis of stem cells and reduce fibrosis in dKO muscle. We then studied whether glucocorticoid treatment can be improved by co-administration of an inhibitor of RhoA / ROCK signaling, which can be activated by glucocorticoids and was found in our previous work to be over-activated in dystrophic muscle. Our results indicate that the combination of RhoA / ROCK inhibition and glucocorticoid treatment in dystrophic muscle have a synergistic effect in alleviating the dystrophic phenotype. Taken together, our study not only shed light on the mechanism by which glucocorticoid imparts its beneficial effect on dystrophic muscle, but also revealed the synergistic effect of RhoA / ROCK inhibition and glucocorticoid treatment, which could lead to the development of more efficient therapeutic approaches for treating DMD patients.
28549178	0	4	RhoA	T103	UMLS:C0643681
28549178	7	11	Rock	T103	UMLS:C0389995
28549178	12	22	Inhibition	T038	UMLS:C2247986
28549178	86	103	Dystrophic Muscle	T038	UMLS:C0026850
28549178	122	131	Stem Cell	T017	UMLS:C0038250
28549178	189	209	palliative treatment	T091	UMLS:C0030231
28549178	214	241	Duchenne muscular dystrophy	T038	UMLS:C0013264
28549178	243	246	DMD	T038	UMLS:C0013264
28549178	270	285	adverse effects	T038	UMLS:C0879626
28549178	304	313	treatment	T058	UMLS:C0087111
28549178	368	383	glucocorticoids	T103	UMLS:C0017710
28549178	412	429	dystrophic muscle	T038	UMLS:C0026850
28549178	458	473	adverse effects	T038	UMLS:C0879626
28549178	505	517	prednisolone	T103	UMLS:C0032950
28549178	518	527	treatment	T058	UMLS:C0087111
28549178	531	541	dystrophin	T017	UMLS:C1414083
28549178	544	552	utrophin	T017	UMLS:C1421412
28549178	553	579	double knockout (dKO) mice	T204	UMLS:C0206745
28549178	604	614	dystrophic	T038	UMLS:C0026850
28549178	638	654	muscle stem cell	T017	UMLS:C0599856
28549178	692	708	muscle stem cell	T017	UMLS:C0599856
28549178	722	725	dKO	T038	UMLS:C1522225
28549178	726	732	muscle	T017	UMLS:C0026845
28549178	747	759	upregulation	T038	UMLS:C0041904
28549178	763	767	mTOR	T103	UMLS:C1447315
28549178	778	790	prednisolone	T103	UMLS:C0032950
28549178	791	800	treatment	T058	UMLS:C1533734
28549178	813	823	expression	T038	UMLS:C1171362
28549178	827	831	mTOR	T103	UMLS:C1447315
28549178	842	868	pro-inflammatory mediators	T103	UMLS:C0574031
28549178	896	912	muscle stem cell	T017	UMLS:C0599856
28549178	933	945	prednisolone	T103	UMLS:C0032950
28549178	946	955	treatment	T058	UMLS:C0087111
28549178	982	992	myogenesis	T038	UMLS:C0596997
28549178	996	1006	stem cells	T017	UMLS:C0038250
28549178	1018	1026	fibrosis	T038	UMLS:C0016059
28549178	1030	1033	dKO	T038	UMLS:C1522225
28549178	1034	1040	muscle	T017	UMLS:C0026845
28549178	1110	1127	co-administration	T058	UMLS:C1533734
28549178	1134	1143	inhibitor	T103	UMLS:C1519313
28549178	1147	1151	RhoA	T103	UMLS:C0643681
28549178	1154	1158	ROCK	T103	UMLS:C0389995
28549178	1159	1168	signaling	T038	UMLS:C0037080
28549178	1196	1211	glucocorticoids	T103	UMLS:C0017710
28549178	1271	1288	dystrophic muscle	T038	UMLS:C0026850
28549178	1335	1339	RhoA	T103	UMLS:C0643681
28549178	1342	1346	ROCK	T103	UMLS:C0389995
28549178	1347	1357	inhibition	T038	UMLS:C2247986
28549178	1390	1407	dystrophic muscle	T038	UMLS:C0026850
28549178	1453	1463	dystrophic	T038	UMLS:C0026850
28549178	1547	1561	glucocorticoid	T103	UMLS:C0017710
28549178	1595	1612	dystrophic muscle	T038	UMLS:C0026850
28549178	1658	1662	RhoA	T103	UMLS:C0643681
28549178	1665	1669	ROCK	T103	UMLS:C0389995
28549178	1670	1680	inhibition	T038	UMLS:C2247986
28549178	1765	1787	therapeutic approaches	T058	UMLS:C0087111
28549178	1801	1804	DMD	T038	UMLS:C0013264